Lopinavir/ritonavir (LPV/r)

DRUG8 trials

Conditions

HIV InfectionHIV InfectionsHIV/AIDSHuman Immunodeficiency Virus InfectionMalariaTuberculosis

Phase 1

Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin

CompletedNCT01571414

National Institute of Allergy and Infectious Diseases (NIAID)Tuberculosis

Start: 2012-05-31End: 2013-05-31Updated: 2021-11-05

Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission

RecruitingNCT02140255

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infection

Start: 2015-01-23End: 2031-12-31Target: 1120Updated: 2026-04-03

Phase 3

Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding

CompletedNCT00640263

French National Agency for Research on AIDS and Viral HepatitisHIV Infections

Start: 2009-12-31End: 2014-02-28Target: 1500Updated: 2014-04-14

Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)

CompletedNCT00711009

AbbottHuman Immunodeficiency Virus Infection

Start: 2008-07-31End: 2010-10-31Updated: 2012-02-14

HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children

CompletedNCT00978068

University of California, San FranciscoHIV Infections, Malaria

Start: 2009-09-30End: 2013-01-31Updated: 2018-12-28

Treatment Options for Protease Inhibitor-exposed Children

CompletedNCT01146873

Columbia UniversityHIV/AIDS, HIV Infections

Start: 2010-07-31End: 2014-12-31Updated: 2017-03-13

Unknown Phase

IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults

CompletedNCT00977756

International Maternal Pediatric Adolescent AIDS Clinical Trials GroupHIV Infections

Start: 2002-08-31End: 2014-03-31Updated: 2015-08-07

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

CompletedNCT04518228

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections, Tuberculosis

Start: 2021-09-01End: 2025-07-10Updated: 2025-11-12

2025-09-25

HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study.

2023-12-0410 citations

Infants Receiving Very Early Antiretroviral Therapy Have High CD4 Counts in the First Year of Life

Clinical Infectious Diseases2022-08-295 citations

The prevalence and socio-behavioural and clinical covariates of oral health related quality of life in Ugandan mothers with and without HIV-1

Health and Quality of Life Outcomes2021-08-2310 citations

Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study.

2020-11-2312 citations

Antiretroviral treatment and its impact on oral health outcomes in 5 to 7 year old Ugandan children

Medicine2020-09-247 citations

Caries experience and oral health related quality of life in a cohort of Ugandan HIV-1 exposed uninfected children compared with a matched cohort of HIV unexposed uninfected children.

2020-03-3016 citations

Clinical and Biological Factors Associated With Early Epstein-Barr Virus Infection in Human Immunodeficiency Virus–Exposed Uninfected Infants in Eastern Uganda

Clinical Infectious Diseases2020-02-1311 citations

Association of maternal HIV‐1 severity with dental caries: an observational study of uninfected 5‐ to 7‐yr‐old children of HIV‐1‐infected mothers without severe immune suppression

European Journal Of Oral Sciences2020-01-295 citations

Lopinavir-Ritonavir Impairs Adrenal Function in Infants

Clinical Infectious Diseases2019-09-0510 citations

Growth in HIV-1-exposed but uninfected infants treated with lopinavir-ritonavir versus lamivudine: a secondary analysis of the ANRS 12174 trial.

2019-02-2411 citations

The Mission is Remission

The Pediatric Infectious Disease Journal2018-10-222 citations

Absence of neurocognitive disadvantage associated with paediatric HIV subtype A infection in children on antiretroviral therapy.

2017-10-018 citations

Switching to Efavirenz Versus Remaining on Ritonavir-boosted Lopinavir in Human Immunodeficiency Virus-infected Children Exposed to Nevirapine: Long-term Outcomes of a Randomized Trial

Clinical Infectious Diseases2017-04-1129 citations

Breastfeeding patterns and its determinants among mothers living with Human Immuno-deficiency Virus -1 in four African countries participating in the ANRS 12174 trial

International Breastfeeding Journal2016-12-0112 citations

Are Prophylactic and Therapeutic Target Concentrations Different?: the Case of Lopinavir-Ritonavir or Lamivudine Administered to Infants for Prevention of Mother-to-Child HIV-1 Transmission during Breastfeeding

Antimicrobial Agents and Chemotherapy2016-11-297 citations

Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial.

2015-11-1962 citations

Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa

JAMA2015-11-0341 citations

Phase I Safety, Pharmacokinetics, and Pharmacogenetics Study of the Antituberculosis Drug PA-824 with Concomitant Lopinavir-Ritonavir, Efavirenz, or Rifampin

Antimicrobial Agents and Chemotherapy2014-06-2451 citations

Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children.

2012-11-0184 citations

Lopinavir/ritonavir (LPV/r)

Sponsors

Conditions

Phase 1

Phase 3

Unknown Phase

Related Papers